Arkolith/Insider Trading/TAK/Form 4

Weber Christophe Pierre

President and CEO, DirectorTAKEDA PHARMACEUTICAL CO LTD (TAK) · full profile →Form 4 · filed Apr 28, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 27, 2026Grant(A)79K—$01.0M
Apr 27, 2026Grant(A)165K—$0419K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 27, 2026Grant(A)79K—$0125K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001395064-26-000140) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML